跳至主要内容
临床试验/CTRI/2021/04/032892
CTRI/2021/04/032892尚未招募2 期

A randomized controlled trial comparing the combination of oral mycophenolate mofetil and topical tacrolimus with topical tacrolimus monotherapy in acquired dermal macular hyperpigmentation

PGIMER0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
PGIMER

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with a diagnosis of ADMH as follows. 21
  • 1. Clinical â?? Hyperpigmented, non-scaly, macules and patches, either discrete or coalescing to form diffuse, blotchy, reticular or follicular patterns (must involve face and/or neck, may involve other body parts concomitantly)
  • 2. Histopathological â?? An ongoing interface dermatitis with prominent melanin incontinence
  • 3. Dermatoscopy â?? Presence of dots and globules.
  • 4. An absent clinically apparent inflammatory phase prior to the appearance of the hyperpigmented patches.
  • Age >18 years.
  • Consenting for inclusion in the study

排除标准

  • Age < 18 years.
  • Patients with gastric and/or hepatic abnormalities.
  • Patients with known hemotological disease
  • Pateints with renal disease.
  • Known hypersensitivity to drug.
  • Clinically cured/ persistent malignancy
  • Active infection or immunodeficiency.
  • Pregnant or lactating women.

研究者

发起方
PGIMER

相似试验